tazarotene has been researched along with Obesity in 2 studies
tazarotene: a topical acetylenic retinoid; a topical kerytolytic
tazarotene : The ethyl ester of tazarotenic acid. A prodrug for tazarotenic acid, it is used for the treatment of psoriasis, acne, and sun-damaged skin.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Psoriasis is a chronic, multisystem, inflammatory disease that affects approximately 1% of children, with onset most common during adolescence." | 1.56 | Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. ( Armstrong, AW; Connor, C; Cordoro, KM; Davis, DMR; Elewski, BE; Elmets, CA; Farley Prater, EA; Gelfand, JM; Gordon, KB; Gottlieb, AB; Hariharan, V; Kaplan, DH; Kavanaugh, A; Kiselica, M; Kivelevitch, D; Korman, NJ; Kroshinsky, D; Lebwohl, M; Leonardi, CL; Lichten, J; Lim, HW; Mehta, NN; Menter, A; Paller, AS; Parra, SL; Pathy, AL; Rupani, RN; Siegel, M; Stoff, B; Strober, BE; Wong, EB; Wu, JJ, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Menter, A | 1 |
| Cordoro, KM | 1 |
| Davis, DMR | 1 |
| Kroshinsky, D | 1 |
| Paller, AS | 1 |
| Armstrong, AW | 1 |
| Connor, C | 1 |
| Elewski, BE | 1 |
| Gelfand, JM | 1 |
| Gordon, KB | 1 |
| Gottlieb, AB | 1 |
| Kaplan, DH | 1 |
| Kavanaugh, A | 1 |
| Kiselica, M | 1 |
| Kivelevitch, D | 1 |
| Korman, NJ | 1 |
| Lebwohl, M | 1 |
| Leonardi, CL | 1 |
| Lichten, J | 1 |
| Lim, HW | 1 |
| Mehta, NN | 1 |
| Parra, SL | 1 |
| Pathy, AL | 1 |
| Farley Prater, EA | 1 |
| Rupani, RN | 1 |
| Siegel, M | 1 |
| Stoff, B | 1 |
| Strober, BE | 1 |
| Wong, EB | 1 |
| Wu, JJ | 1 |
| Hariharan, V | 1 |
| Elmets, CA | 1 |
| Weisshaar, E | 1 |
| Bonnekoh, B | 1 |
| Franke, I | 1 |
| Gollnick, H | 1 |
2 other studies available for tazarotene and Obesity
| Article | Year |
|---|---|
Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients.
Topics: Adolescent; Adrenal Cortex Hormones; Anthralin; Biological Products; Calcineurin Inhibitors; Cardiov | 2020 |
[Successful symptomatic tazarotene treatment of juvenile acanthosis nigricans of the familial obesity-associated type in insulin resistance].
Topics: Acanthosis Nigricans; Administration, Topical; Child; Diabetes Mellitus; Diabetes Mellitus, Type 2; | 2001 |